North America Anal Fistula Treatment Market Size & Outlook, 2026-2034
North America Anal Fistula Treatment Market Insights
- As highlighted in Reed Intelligence analysis, the North America Anal Fistula Treatment Market, valued at USD 345.12 Million in 2025, is estimated to achieve USD 658.85 Million by 2034.
- The market is estimated to grow at a CAGR of 7.48% spanning 2026 to 2034.
- By market size, Surgical Treatment led the Treatment Type category in 2025.
- The Treatment Type segment led by Minimally Invasive Treatment is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, North America contributed 30.01% to the overall global Anal Fistula Treatment Market size.
- By 2034, United States is anticipated to dominate the global market based on market size.
- Canada is expected to witness the fastest growth within North America, attaining USD 159.78 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 345.12 Million |
| Market Size In 2034 | USD 658.85 Million |
| Largest segment | Surgical Treatment |
| Units | Revenue in USD Million |
| CAGR | 7.48% (2026-2034) |
| Segmnetation Covered | |
| North America |
|
| Treatment Type |
|
| Product Type |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
North America Anal Fistula Treatment Market Country 2026-2034 (USD Million)
| North America | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | XX.x | XX.x | XX.x | 263.71 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Canada | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Anal Fistula Treatment Market Treatment Type 2026-2034 (USD Million)
| Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Treatment | XX.x | XX.x | XX.x | 214.73 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Minimally Invasive Treatment | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Anal Fistula Treatment Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biologics (Fibrin Glue, Anal Fistula Plugs) | XX.x | XX.x | XX.x | 208.07 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Stem Cell-Based Products | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Anal Fistula Treatment Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 208.21 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
